Algert Global LLC Cuts Stake in Syndax Pharmaceuticals

Institutional investor reduces holdings in clinical-stage biotech company

Mar. 15, 2026 at 7:23am

Got story updates? Submit your updates here. ›

Algert Global LLC, an institutional investor, has reduced its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 8.9% in the third quarter, according to a recent SEC filing. The firm now owns 930,766 shares of the company's stock, worth approximately $14.3 million.

Why it matters

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies. Tracking institutional investor activity can provide insights into market sentiment and potential future performance of the company's stock.

The details

According to the 13F filing, Algert Global LLC sold 90,514 shares of Syndax Pharmaceuticals during the third quarter. The firm now owns about 1.07% of the company's outstanding shares. Syndax Pharmaceuticals is developing several investigational cancer treatments, including its lead candidate entinostat, a selective class I histone deacetylase (HDAC) inhibitor.

  • Algert Global LLC reduced its Syndax Pharmaceuticals holdings in the 3rd quarter of 2026.

The players

Algert Global LLC

An institutional investor that has reduced its stake in Syndax Pharmaceuticals.

Syndax Pharmaceuticals, Inc.

A clinical-stage biopharmaceutical company focused on developing novel cancer therapies.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Algert Global's Syndax Pharmaceuticals holdings could signal a shift in market sentiment around the biotech company's prospects, though more data would be needed to draw definitive conclusions. Investors will likely continue to monitor Syndax's pipeline progress and institutional investment activity.